Testimony Before the FDA’s Vaccines and Related Biological Products Advisory Committee Regarding Booster Doses of the Moderna COVID-19 Vaccine

View as PDF

In testimony before a meeting of the Food and Drug Administration’s (FDA’s) Vaccines and Related Biological Products Advisory Committee, Public Citizen highlighted three limitations regarding the clinical trial data submitted in support of Moderna’s request for an emergency use authorization for a booster (third) dose of the company’s COVID-19 vaccine.

See Public Citizen’s other work on the COVID-19 pandemic.